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The use of 2D fingerprint methods to support the
assessment of structural similarity in orphan drug
legislation
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Abstract
Background: In the European Union, medicines are authorised for some rare disease only if they are judged to be
dissimilar to authorised orphan drugs for that disease. This paper describes the use of 2D fingerprints to show the
extent of the relationship between computed levels of structural similarity for pairs of molecules and expert
judgments of the similarities of those pairs. The resulting relationship can be used to provide input to the
assessment of new active compounds for which orphan drug authorisation is being sought.
Results: 143 experts provided judgments of the similarity or dissimilarity of 100 pairs of drug-like molecules from
the DrugBank 3.0 database. The similarities of these pairs were also computed using BCI, Daylight, ECFC4, ECFP4,
MDL and Unity 2D fingerprints. Logistic regression analyses demonstrated a strong relationship between the human
and computed similarity assessments, with the resulting regression models having significant predictive power in
experiments using data from submissions of orphan drug medicines to the European Medicines Agency. The BCI
fingerprints performed best overall on the DrugBank dataset while the BCI, Daylight, ECFP4 and Unity fingerprints
performed comparably on the European Medicines Agency dataset.
Conclusions: Measures of structural similarity based on 2D fingerprints can provide a useful source of information
for the assessment of orphan drug status by regulatory authorities.
Keywords: Drug registration, European Medicines Agency, Fingerprint, Molecular similarity, Ophan drug, Similarity
Background
The discovery, testing and registration of a novel drug is
both time-consuming and extremely expensive, with a
review by Morgan et al. quoting costs in the range $161
million to $1.8 billion for the development of a novel
therapeutic agent [1]. Such huge costs are acceptable to
a pharmaceutical company if, and only if, there is a rea-
sonable expectation that they can be recouped and a
profit achieved when the drug is made available to large
numbers of patients suffering from the target disease.
There are, however, many diseases where there is a clear
need for treatment but where there are insufficient pa-
tients world-wide to support the costs of modern drug
research. These medical conditions are normally referred
to as rare diseases and there is much current interest in
the development of orphan drugs for the treatment of
such diseases [2-4].
There is no single definition of a rare disease, since ac-
count may need to be taken not only of the number of pa-
tients affected by it but also its severity and the availability
of existing, adequate treatments. Different regulatory au-
thorities have hence adopted rather different definitions
[5-7]. In the European Union (EU), which is the context
for this paper, the evaluation of orphan drugs is coordi-
nated by the European Medicines Agency (hereafter the
EMA). According to article 3 (1) of Regulation (EC) No
141/2000 of the European Parliament and of the Council
of 16 December 1999 on orphan medicinal products, a
medicine must meet a number of criteria if it is to qualify
as an orphan drug: “it must be intended for the treatment,
prevention or diagnosis of a disease that is life-threatening
or chronically debilitating; the prevalence of the condition
in the EU must not be more than 5 in 10,000 or it must be
unlikely that marketing of the medicine would generate
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sufficient returns to justify the investment needed for
its development; and no satisfactory method of diagno-
sis, prevention or treatment of the condition concerned
can be authorised, or, if such a method exists, the medi-
cine must be of significant benefit to those affected by
the condition”.
The EU provides a range of incentives to encourage
the development of orphan drugs, the most important
of which is a high level of market exclusivity: once a
medicine has been awarded an orphan drug authorisa-
tion by the European Commission, no similar medicinal
product can be brought to the European market for a
period of ten years. The criteria and incentives were de-
tailed formally, in the regulation noted above, but with-
out any explicit specification of the nature or the extent
of the similarity required to define a “similar medicinal
product”. This lack was addressed, in part at least, in a
subsequent regulation - Commission Regulation (EC) No
847/2000 of 27 April 2000 laying down the provisions
for implementation of the criteria for designation of a
medicinal product as an orphan medicinal product and
definitions of the concepts ‘similar medicinal product’
and ‘clinical superiority’ - which defined a similar active
substance as “an identical active substance, or an active
substance with the same principal molecular structural fea-
tures (but not necessarily all of the same molecular struc-
tural features) and which acts via the same mechanism”.
When a company applies to register a new medicine for
an indication that has already been granted for an orphan
medicine it is the responsibility of the EMA’s Committee
for Medicinal Products for Human Use (CHMP) to decide
if the new drug is indeed similar to an existing orphan
drug, with an application being successful only when the
CHMP decides that this is not the case. To date, the eval-
uations carried out by the CHMP have been based largely
on human judgments of similarity. In this paper, we dis-
cuss the use of computed measures of structural similarity
based on 2D fingerprints to provide an additional source
of information that could be used when the CHMP con-
siders the relationships that may exist between existing
and proposed new medicines for rare diseases.
Results and discussion
Human similarity judgements
The 143 experts provided Yes/No decisions on the
training-set of 100 DrugBank 3.0 molecule-pairs as de-
tailed in Additional file 1: Table S1 (see Experimental
methods). Figure 1 shows three typical pairs, the corre-
sponding proportions of Yes/No responses to the question
“Are these molecules similar?”, and the Tanimoto similar-
ity computed using ECFP4 fingerprints.
The distribution of the similarity judgments provided
by the experts for each of the molecule-pairs is shown in
Figure 2. The left-hand column of the plot shows, for
Molecule A Molecule B Yes No Similarity
0.93 0.07 0.865
0.14 0.86 0.432
0.59 0.41 0.595
Figure 1 Three training-set molecule-pairs with the corresponding fractions (n = 143) of Yes/No responses to the question “Are these
molecules similar?” The similarity values in the right-hand column are those obtained using the Tanimoto coefficient and ECFP4
fingerprints.
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example, that there were 38 molecule-pairs where < 0.1
of the judgments were that the molecules were similar
(i.e., the great majority of the experts considered these to
be non-similar molecule-pairs); the right-hand column,
conversely, shows that there were 21 molecule-pairs
where ≥0.9 of the judgments were that the molecules
were similar (i.e., the great majority of the experts consid-
ered these to be similar molecule-pairs). If the experts
had been in total agreement with each other then the
plot would simply have consisted of these two columns,
without any of the intervening columns, which denote
molecule-pairs where there was some level of disagree-
ment. However, inspection of the plot shows that there
were 41 molecule-pairs with fractions in the range 0.1-0.9,
including nine where very considerable levels of disagree-
ment were evident, viz the two middle columns represent-
ing the molecule-pairs where 0.4-0.6 of the experts felt
that the two molecules were similar.
We ascribe these levels of disagreement to the inher-
ently subjective nature of similarity [8,9], with an individ-
ual’s perception that two objects are similar depending on
a range of factors (such as their state of mind, gender, age,
personality and previous scientific experience inter alia).
That being so, it is hardly surprising that different experts
responded in different ways to the molecule-pairs that
were presented to them, a finding that is consistent with
previous experimental studies that have demonstrated that
different individuals do not perceive chemical structure
information in the same way. For example, Lajiness et al.
report a study of medicinal chemists at Pharmacia, who
were asked to review lists of compounds in order to assess
their potential as leads in a drug discovery programme
[10]; not only were there marked inconsistencies between
the chemists, but even the same chemist might give
different assessments on different occasions. Hack et al.
reported an analogous study that sought to enhance the
diversity of the Johnson & Johnson corporate structure
database; they found that whilst there were considerable
differences between individual chemists a fair level of
consistency could be achieved using a wisdom-of-crowds
approach [11]. This technique was also used by Oprea
et al. to reconcile the often disparate views of pharma-
ceutical experts as to the effectiveness of chemical
probes resulting from the NIH Molecular Libraries and
Imaging Initiative [12]. Boda et al. [13] and Bonnet [14]
studied groups of medicinal chemists’ assessments of
molecular synthetic feasibility, and again observed some
degree of inconsistency in the judgments that were
made. Finally, Kutchukian et al. have reported a large-
scale study of medicinal chemists at Novartis, who were
asked to select chemical fragments for lead-generation
projects. There was not only a marked level of incon-
sistency in the selection, but also a comparable level of
inconsistency in the reasons for their selections [9].
Analogous variations in the ways that individuals react
to objects have been widely observed: for example,
when indexing terms are assigned to documents [15],
when links are created in hypertext systems [16], when
search strategies are chosen for accessing text databases
[17], and when scientists create mental maps of active
research areas [18].
We note here one characteristic of the training data
that could have affected the results, which is the way
that the molecules were presented to the experts for as-
sessment. In some cases, the molecules in a pair were
displayed in such a way that the structural similarities
were obvious to the human eye with the common fea-
tures clearly aligned, as exemplified by the molecules in
the first row of Figure 1. In other cases, the similarities
may have been less obvious when the common features
were not aligned, as exemplified by the molecules in the
third row of Figure 1. Such variant alignments could re-
sult in the experts perceiving the molecules comprising
a pair to be less similar than might have been expected
from one or more of the computed, fingerprint-based
similarities. The alignments presented to the experts
(such as the examples above and the molecule-pairs in
Additional file 1: Table S1) were those available in the
DrugBank database. No attempt was made to modify the
alignments in cases where it was felt that improvements
were possible (such as the example above), since this is
the situation faced by the members of the CHMP when
they consider applications for authorisation; indeed, they
have the additional problem that the molecule-pairs that
they inspect (i.e., a molecule that has been submitted for
consideration and the existing orphan-drug for that dis-
ease) may well have been drawn using different drawing
packages.
Figure 2 Distribution of expert assessments on the training-set.
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Logistic regression, receiver operating characteristic
curves and performance statistics
Once the human judgments had been determined and
the similar and non-similar molecular-pairs identified, it
was possible to develop logistic regression models that
assessed how fingerprint-based similarities were correlated
with the probability of being considered similar by the ma-
jority of the experts. For each fitted model, ROC curves
and other performance statistics were computed in order
to assess the predictive performance of each fingerprint.
The analysis is exemplified by the logistic regression model
for the ECFP4 fingerprint, with the same processes being
applied to each of the fingerprints.
Figure 3 plots the proportion of the expert assessors
who judged a molecule-pair as being similar (Y-axis)
against the computed ECFP4 similarity score for that
molecule-pair (X-axis). It will be seen that there is an ex-
cellent separation of similar and non-similar molecular
pairs (in green and blue, respectively), with smaller ECFP4
values corresponding to molecules considered not similar,
and greater ECFP4 values corresponding to those consid-
ered similar. In addition to the observed data, the solid
line in Figure 3 represents the estimated probability of be-
ing similar as predicted by the logistic regression model
(together with the 95% confidence limits for this predic-
tion). Table 1 contains the estimates of β0 and β1 for the
ECFP4 regression model (see Experimental methods for
the definition of these parameters), which are −12.754 and
2.524, respectively. The latter value means that for each
increment of 0.1 in the ECFP4 score, the odds of a
molecule-pair being classified as similar are multiplied by
exp(2.524), i.e., 12.48 times. The Nagelkerke R2 value is
high (0.894), indicating a good fit of the model to the data.
The computed value for the threshold similarity (i.e., the
ECFP4 value for which the corresponding probability of
being classified as similar by the experts is 0.5), tLR, is
0.505. The ECFP4 ROC curve is shown in Figure 4, where
it will be seen that a very high AUC value (0.988) is ob-
tained, indicating the ability of this fingerprint to discrim-
inate between similar and non-similar molecule-pairs.
The corresponding results for all of the six fingerprints
are listed in Table 1, with the fingerprints listed in alpha-
betical order. As with the ECFP4 fingerprint, goodness-
of-fit assessment was performed for all fingerprints and
the assumptions of each fitted model were assessed with
the Hosmer-Lemenshow test. The Nagelkerke R2 values
were high (>0.8) for all fingerprints. In the case of the
Unity data, the model listed in Table 1 is that obtained
after the elimination of one outlier molecule-pair (number
99 in Additional file 1: Table S1), where over 70% of the
Figure 3 Plot of the proportion of experts who assessed a
training-set molecule-pair as being similar against the ECFP4
similarity for that molecule-pair. The figure also shows the
computed logistic regression curve (and 95% confidence limits) for
this fingerprint.
Table 1 Logistic regression to predict the similarity, or
otherwise, of training-set molecule-pairs using different
types of fingerprint
Fingerprint β0 β1 R
2
tLR AUC
BCI −12.758 2.128 0.906 0.599 0.990
Daylight −10.677 1.850 0.884 0.577 0.986
ECFC4 −9.207 2.438 0.878 0.378 0.983
ECFP4 −12.754 2.524 0.894 0.505 0.988
MDL −9.022 1.380 0.812 0.654 0.973
Unity −12.347 1.956 0.884 0.631 0.987
The columns contain the β0 and β1 values for the logistic regression model,
the Nagelkerke R2 value, the computed value for tLR and the AUC for the
ROC curve.
Figure 4 ROC curve for ECFP4 fingerprints.
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experts judged the pair to be similar despite a Unity simi-
larity of just 0.217. When this molecule pair was included
in the model, the assumptions of the logistic regression
did not hold: removing this observation, nevertheless, did
not change significantly the estimates of β0 and β1.
As discussed below (see Experimental methods), the
various performance statistics were computed as the
value of t, the threshold similarity, was systematically
varied, so as to determine the cut-off value, tROC, that
resulted in the best overall predictive performance. The
results of these experiments are shown in Table 2, in the
column headed Probability, which lists the probability
that a molecule-pair will be judged as similar if the simi-
larity fingerprint value is at least the specified value of
tROC. It will be seen that the best overall performance
would appear to come from use of the BCI fingerprints
with a similarity threshold of 0.606, this giving the
largest observed values for the accuracy, the F index, the
Youden index and the Matthews coefficient, and the sec-
ond largest observed value for the precision. The tROC
values in this table are very close to the corresponding
tLR values in Table 1, with the sole exception of the Day-
light fingerprints (0.510 and 0.577, respectively). This
was expected as the prevalence of similar molecules in
the training-set was close to 50%, the probability cut-off
used to compute tLR.
Use of an external test-set
As described in Experimental methods, a test-set of 100
molecule-pairs was created using data from previous ap-
plications to the CHMP for orphan-drug registration. A
comparison of the characteristics of these test-set mole-
cules with those in the training-set can be found in
Table 3. The Tanimoto similarities were computed for
each test-set molecule-pair using each of the six finger-
prints, and similarity or non-similarity predicted using
the tLR and tROC thresholds developed from the training-
set. The results obtained are shown in Table 4, where it
will be seen that in all cases the choice of threshold has
little or no difference in predictive ability and, import-
antly, that all but the MDL and ECFC4 fingerprints
performed extremely well. The MDL performance is in
line with that observed in Table 2 (where it was the
worst overall performer) but that for ECFC4 is notably
poor: it was the second-worst performer in Table 2 but
its performance here is far inferior to that of all of the
other fingerprints. Inspection of the 29 molecule-pairs
where it failed provided no obvious reason for the incor-
rect predictions; indeed, given that these test-set mole-
cules are rather larger than those in the training-set this
fingerprint might have been expected to do particularly
well as it takes account of how frequently each fragment
substructure occurs, rather than just its presence or
absence as in the other fingerprint-types.
A simple consensus approach was then used to see if
further improvements could be made. A molecule-pair
was classified as similar or non-similar by each of the
fingerprints individually, and then the final classification
was similar if three or more of the individual classifica-
tions were similar. This consensus result forms the bottom
row of Table 4.
Conclusions
In this paper, we have described how fingerprint-based
measures of similarity can be used to assess the struc-
tural novelty of molecules that are being submitted for
consideration as new medicines for rare diseases. Such
measures are well established, dating back to at least the
mid-1970s [19], for applications such as property predic-
tion, cluster analysis and virtual screening. A characteris-
tic of most of these studies is that they have focused on
the identification of molecules that are similar to each
other; in similarity-based virtual screening, for example,
the aim is to identify those previously untested database
structures that are most similar to a bioactive reference
structure [20,21], whilst removing the large numbers of
low-similarity database structures from further consider-
ation. In the current application, conversely, dissimilarity
is of at least as much importance as is similarity; indeed,
it is arguably of greater importance for a company apply-
ing for orphan drug authorisation. The other chemoin-
formatics application where dissimilarity is important is
Table 2 Optimal levels of performance using ROC curves
Fingerprint tROC Probability Sensitivity Specificity Precision Accuracy F Youden Matthews
BCI 0.606 0.534 0.980 0.941 0.941 0.960 0.960 0.921 0.9208
Daylight 0.510 0.225 1.000 0.882 0.891 0.940 0.942 0.882 0.8866
ECFP4 0.490 0.406 0.980 0.922 0.923 0.950 0.951 0.901 0.9017
ECFC4 0.364 0.415 0.980 0.882 0.889 0.930 0.932 0.862 0.8645
MDL 0.650 0.487 0.939 0.882 0.885 0.910 0.911 0.821 0.8216
Unity 0.639 0.537 0.938 0.961 0.957 0.950 0.947 0.898 0.8990
tROC is the similarity threshold that gives the best level of performance, where this is that similarity value which maximises the values of the precision, the
accuracy, the F index, the Youden index and the Matthews coefficient whilst maintaining acceptable values of the sensitivity and specificity. The largest values of
these last five variables are bold-faced in the table.
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molecular diversity analysis; however the identification
of sets of mutually dissimilar molecules is very different
from the need to determine whether two molecules are
considered to be significantly different as is required for
the current application.
The results obtained here demonstrate clearly that
simple, 2D fingerprint representations provide measures
of structural similarity that mimic closely the judgments
of experts, using both training-set molecule-pairs ex-
tracted from DrugBank and test-set molecule-pairs typ-
ical of the work of the CHMP. This is so despite the fact
that the two sets of molecules are rather different in
character (as demonstrated by the figures in Table 3).
The BCI fingerprints performed best overall on the
training-set while the BCI, Daylight, ECFP4 and Unity
fingerprints showed comparable, high levels of predict-
ive performance on the test-set. The BCI fingerprints
would hence seem to be an appropriate choice for
future studies in this area. They encode six different
classes of chemical substructure: augmented atoms, atom/
bond sequences, atom pairs, and three types of ring
feature. The atom- and bond-types can be generalized if
required and an algorithmic procedure is used to select
the required number of substructures (1052 in the
present case) whilst ensuring that they satisfy user-
specified criteria relating to minimum, maximum and
co-occurrence frequencies.
There are, of course, similarity measures other than
those studied to date that could be used for the study of
orphan drug similarity, e.g., a measure that takes ac-
count of 3D structural information or that uses a simi-
larity coefficient other than the Tanimoto coefficient.
Other possible areas of study include the use of multiple
similarity measures in the logistic regression model, ac-
counting for individual judgements instead of using the
majority decision, or the use of more sophisticated data
fusion methods [22] than the simple consensus approach
considered thus far.
In conclusion, we must emphasise that we are not sug-
gesting that a computational procedure could be used as
an alternative to, let alone a replacement for, the current
processes used to evaluate applications for orphan drug
authorisations. However, the approach described here
could form a useful, quantitative input to those evalua-
tions by providing a tool to assess molecular structural
similarity by interested parties. Assume that a new mol-
ecule M is being submitted for orphan drug authorisa-
tion, and that there is already an existing drug D for
this indication. The similarity between M and D is
computed, e.g. using one of the fingerprint-types that
performed well in the experiments above, and then the
corresponding regression equation used to give the
probability that the two molecules would be considered
a similar molecule-pair, based upon experts’ previous
similarity assessments. This probability would then be
one of the multiple factors that are considered when
deciding upon the similarity or otherwise between M
and D [23].
Experimental methods
In the evaluation of similarity in the context of orphan
drug evaluation, the CHMP needs to decide whether or
not an active compound for which a new medicine, or
an extension of an existing marketing authorisation
(change of indication or line extension), is being sought
is similar to an existing orphan drug that has already
been authorised. The decision is made on the basis of
the votes of a panel of experts drawn from each of the
member states of the EU. Focussing just on the similar-
ity criterion, the experts are required to make a binary
decision: is the new molecule similar to, or different
from, the existing orphan drug(s) for the rare disease of
interest? The experimental set-up that we have created
seeks to mimic this situation, with a panel of experts be-
ing asked to make judgements on the similarity or other-
wise of a carefully chosen training-set of molecule-pairs,
and then a comparison being made between these hu-
man decisions and the outputs from computer-based
similarity calculations. In this section, we describe the
following components of our experimental procedure:
the training-set of molecule-pairs on which the similarity
Table 4 Numbers of test-set molecule-pairs predicted
correctly using tLR and tROC
Fingerprint tLR tROC
BCI 97 97
Daylight 97 98
ECFP4 96 97
ECFC4 71 71
MDL 92 92
Unity 97 97
Consensus 98 98
Table 3 Characteristics of the 163 training-set and 51
test-set molecules
Training-set Test-set
Molecular weight 301 (100–500) 392 (150–1950)
Number of carbons 16 (5–26) 22 (0–86)
Number of heteroatoms 5 (1–11) 9 (3–52)
Number of rings 2 (0–5) 3 (0–11)
Number of aromatic rings 2 (0–4) 1 (0–3)
Number of stereocentres 1 (0–9) 1 (0–15)
Each element of the table lists the median value, together with the
corresponding range in brackets.
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assessments were made; the panel of experts who made
these assessments; measuring the effectiveness of the au-
tomated assessments; and, finally, a second, independent
test-set of molecule-pairs that was used to assess the
predictive performance of the models developed from
the training-set.
The training-set
The training-set database contains 100 pairs of bioactive
molecules selected from DrugBank 3.0 (at http://www.
drugbank.ca/), a bioinformatics and chemoinformatics
resource that contains a wealth of detailed information
on over six thousand drug molecules and their associ-
ated biological targets [24]. The file was filtered to iden-
tify 1068 molecules that contained at least one carbon
atom and that had not more than ten hydrogen bond
accepters, not more than five hydrogen bond donors, a
molecular mass not greater than 500 Daltons, and an
octanol-water partition coefficient not greater than 5.
The similarity between each distinct pair of these drug-
like molecules was computed using ECFP4 fingerprints
[25] and the Tanimoto coefficient [26], and then 100
pairs of molecules chosen so as to cover as wide and as
equal a spread of Tanimoto values as possible, with the
observed similarity values ranging from 0.116 to 1.000.
The molecule-pairs contained a total of 163 distinct
molecules, these representing 42 different pharmaco-
logical classes including antibiotics, beta-adrenergic an-
tagonists, benzodiazepines and anti-hypertensives inter
alia.
The experts
With the permission of the EMA, one of us (PF) gave
presentations to several EMA committees and working
parties responsible for the evaluation and the quality of
medicines. The attendees at these meetings who had a
background in quality and experience in assessing or-
phan drugs were invited to participate in the project by
providing similarity judgments on the 100 pairs of Drug-
Bank molecules. Similar invitations were sent to appro-
priate individuals on an EMA email list of European
experts with a background in the quality of medicines,
and to contact points in the regulatory authorities in
the USA, Japan and Taiwan (the Food and Drug
Administration, the Pharmaceutical and Medical De-
vices Agency, and the Food and Drug Administration
of Taiwan, respectively). Participants were sent the 100
pairs of 2D structure diagrams and for each molecule-
pair asked to state whether (Yes) or not (No) the two
molecules should be regarded as being structurally
similar. A total of 143 completed responses (128 from
within the EU) was obtained and these were then used
to compute the fractions of Yes and No responses for
each of the pairs of molecules. The structure diagrams
and SMILES descriptions for the 100 molecule-pairs
and the percentages of Yes and No responses for each
such pair are listed in Additional file 1: Table S1.
The decisions of the CHMP are decided on the basis
of majority voting, and it was hence decided that the
molecule-pairs in the sample where more than 50% of
the responses were Yes should be considered as similar,
which we shall refer to as a similar molecule-pair. If this
was not the case then the two molecules were judged to
be a non-similar molecule-pair. This resulted in 49 similar
molecule-pairs and 51 non-similar molecules-pairs; then,
once each of the molecule-pairs had been categorised in
this way, the expert judgments were used to assess the
categorisation ability of similarity measures based on
2D fingerprints.
Measurement of effectiveness
Many different types of structural representation can be
used to compute inter-molecular structural similarities.
The similarities here were computed with 2D finger-
prints, which are widely used for this purpose since they
are both simple to compute and effective in operation
[26,27]. The following types of fingerprint were gener-
ated to represent the molecules in each of the pairs: BCI
(1052), Daylight (2048), ECFC4 (1024), ECFP4 (1024),
MDL (166) and Unity (988), where the number in
brackets is the number of elements in the fingerprint.
Brief descriptions of all these types of fingerprint are
provided by Gardiner et al. [28]. The Tanimoto coeffi-
cient was used to compute the similarity between the
fingerprints for each of the molecules comprising a
molecule-pair, using each type of fingerprint in turn. In
addition, 23 computed molecular properties (such as
molecular weight, logP, pKa, molar refractivity, PSA,
numbers of rotatable bonds and stereocentres etc.) were
computed using Pipeline Pilot to provide an additional
type of structure representation. However, the results
obtained using this representation were uniformly infer-
ior to those obtained using the various 2D fingerprints,
and the results and discussion hence consider only the
fingerprint-based similarity data.
The ability of each type of fingerprint to predict similar-
ity between molecules was determined using logistic re-
gression, receiver operating characteristic (ROC) curves,
and a range of measures of predictive success taken from
the information retrieval and machine learning literatures.
For the logistic regression analysis, let p be the probability
that the panel will conclude that two molecules do indeed
comprise a similar molecule-pair given a computed simi-
larity x. Then logistic regression yields an equation of the
form
logit pð Þ ¼ ln
p
1−p
 
¼ β0 þ β1x
Franco et al. Journal of Cheminformatics 2014, 6:5 Page 7 of 10
http://www.jcheminf.com/content/6/1/5
that describes a linear relationship between the similarity
and the logarithm of the odds that the molecules com-
prise a similar molecule-pair [29]. The performance of
the model can be assessed by observing the differences
between the sets of observed and predicted values: this
was done here using Nagelkerke’s R2 statistic, which
takes values between zero and unity (denoting a very
poor fit and a perfect fit, respectively). Also, Hosmer-
Lemenshow goodness-of-fit tests were used to assess the
assumptions of the model (i.e., linearity at the log scale
and additivity). Once the logistic regression equation for
a fingerprint had been generated, it was used to compute
the threshold similarity, tLR, such that the two molecules
comprising a pair are predicted to be similar (‘Yes’) if
their computed similarity is ≥ tLR (corresponding to a
probability greater than or equal to 0.5 of being similar
according to the logistic regression model) or predicted
to be not similar (‘No’) if < tLR (corresponding to a prob-
ability lower than 0.5 of being similar according to the
logistic regression model).
The chosen cut-off probability of 0.5 may not neces-
sarily be the best value to discriminate between similar
and non-similar pairs. ROC curves built from the pre-
dicted probabilities of the logistic model provide an al-
ternative way of identifying an appropriate threshold
similarity, here called tROC, for deciding that two mole-
cules represent a similar molecule-pair. Assume that a
particular similarity measure has been chosen. Then let
t denote some threshold similarity for that measure
such that the two molecules comprising a pair are pre-
dicted to be similar if their computed similarity is ≥ t and
not similar if < t (in the same way as defined for tLR).
These predictions can then be compared with the expert
judgements in terms of true positives (TP), true negatives
(TN), false positives (FP) and false negatives (FN) where,
e.g., TP is the number of cases where the majority of the
experts judged two molecules to form a similar molecule-
pair and where those two molecules had a computed
similarity ≥ t. Knowing these four values it is possible to
compute the specificity,
TN
TN þ FP
;
and the sensitivity,
TP
TP þ FN
;
for that value of t, and hence to plot the ROC curve
obtained by systematically varying t. The area under
the curve (hereafter AUC) then provides a measure of
the extent to which the computed similarity measure
mirrors the expert judgements, with values close to unity
indicating the highest levels of agreement. In addition to
specificity and sensitivity, the following performance
statistics were computed: the precision
TP
TP þ FP
;
the accuracy
TP þ TN
TP þ TN þ FP þ FN
;
the F index
2 TP
2 TP þ FP þ FN
;
the Youden index
TP  TP−FP  FN ;
and Matthew’s correlation coefficient
TP  TN−FP  FNﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
TP þ FPð Þ TP þ FNð Þ TN þ FPð Þ TN þ FNð Þ
p ;
These performance statistics were computed as the
value of t was systematically varied, so as to determine
tROC, i.e., the threshold similarity that resulted in the best
overall predictive performance. The best level of perform-
ance was taken to be that threshold similarity which re-
sulted in the maximum values for the precision, the
accuracy, the F index, the Youden index and the Matthews
coefficient whilst maintaining acceptable values of the
sensitivity and specificity.
The test-set
The predictive power of the models derived from the
similarity data for the 100 DrugBank molecule-pairs could
have been assessed by means of cross validation experi-
ments using that training-set, as is often done in SAR and
QSAR studies. It is generally considered better, however,
to use a distinct test-set that has not been involved in the
training [30,31], and this was accomplished here using
data kindly provided by the CHMP that typifies their
regular work-load. Specifically, the test-set contained
100 molecule-pairs in which one molecule was an exist-
ing orphan drug for some specific rare disease and the
other was a molecule that had been submitted to the
CHMP for consideration for orphan drug status for that
disease.
It should be noted that the test-set differs from the
training-set in two principal ways. First, of the 100
molecule-pairs provided by the CHMP, 89 of them had
been judged to be non-similar pairs with only 11 judged
to be similar pairs, whereas the test-set contained near-
equal numbers of the two types of molecule-pair. This is
not unexpected given that companies are unlikely to
submit for consideration molecules that are obviously
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closely related to existing orphan drugs for some disease.
Second, the natures of the molecules involved. It is not
possible to provide structural data analogous to that pre-
sented in Additional file 1: Table S1 given the highly
confidential nature of the application process. However,
some broad characteristics of the test-set are as follows.
There were 51 distinct molecules in the test-set, since
many of the molecule-pairs resulted from the comparison
of an existing orphan drug with several different molecules
that had sought authorisation for the same rare disease.
Just five pharmacological classes were represented: there
were two immunosuppressants, two respiratory system
compounds, three antimicrobials, ten pulmonary arterial
hypertension compounds, and no less than 34 antineo-
plastic compounds (reflecting the fact that much current
orphan drug research focuses on therapies for rare types
of cancer [7]). The compounds were notably larger than
those in the test-set as demonstrated in Table 3, with
27.5% of them not being Lipinski-compliant.
Additional file
Additional file 1: Table S1. The 100 molecules-pairs from DrugBank 3.0
that comprised the training-set on which the 143 experts provided Yes/
No decisions.
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